2666940-97-0

2666940-97-0 structure
2666940-97-0 structure
  • Name: Trametiglue
  • Chemical Name: Trametiglue
  • CAS Number: 2666940-97-0
  • Molecular Formula: C25H24FIN6O5S
  • Molecular Weight: 666.46
  • Catalog: Signaling Pathways MAPK/ERK Pathway MEK
  • Create Date: 2023-06-04 10:54:20
  • Modify Date: 2024-04-06 22:34:00
  • Trametiglue, a derivative of Trametinib (HY-10999), targets both KSR-MEK and RAF-MEK with unprecedented potency and selectivity via unique interfacial binding interactions[1].

Name Trametiglue
Description Trametiglue, a derivative of Trametinib (HY-10999), targets both KSR-MEK and RAF-MEK with unprecedented potency and selectivity via unique interfacial binding interactions[1].
Related Catalog
Target

MEK1

MEK2

In Vitro Trametiglue 在 KSR 结合的 MEK 上保留了 Trametinib 较强的结合力和停留时间[1]。 Trametiglue 与 Trametinib 不同,但与 Avutometinib (HY-18652) 相似,可增强内源性 BRAF 与 MEK1 之间的相互作用[1]。 Trametiglue (1 μM) 在直接结合实验中对 MEK1 和 MEK2 具有高选择性。Trametiglue 在抑制上游激酶对 MEK1 和 MEK2 底物磷酸化或直接 MEK1 磷酸化的一组活性激酶中也显示出高选择性[1]。 Trametiglue (5 days) 抑制 HCT116、A375、A549 和 SK-MEL-239 细胞活力,IC50 分别为 0.07、0.07、0.12 和 0.47 nM[1]。 Trametiglue (10 nM; 10 days) 抑制 KRAS 突变和 BRAF 突变癌细胞的集落形成,其效力高于 Trametinib [1]。 Cell Viability Assay[1] Cell Line: SK-MEL-239, HCT116, A549 and A375 Concentration: Incubation Time: 5 days Result: Showed IC50s of 0.47, 0.07, 0.12 and 0.07 nM against SK-MEL-239, HCT116, A549 and A375 cells, respectively. Western Blot Analysis[1] Cell Line: A549, HCT-116, A375 and SK-MEL-239 Concentration: 0.4, 0.8, 1.6, 3.1, 6.25, 12.5, 25 and 50 nM Incubation Time: 1 h Result: Inhibited the expression of pERK. And the effect was better than Trametinib.
References

[1]. Khan ZM, et al. Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature. 2020 Dec;588(7838):509-514.  

Molecular Formula C25H24FIN6O5S
Molecular Weight 666.46
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.